Elasmogen, which is part of the Deepbridge Life Sciences EIS fund, recently entered into a global license agreement with Intract Pharma Limited that gives Elasmogen exclusive access to Soteria® and Phloral® Technologies for oral colonic delivery of therapeutic proteins, deriving from Elasmogen's soloMER™ platform, for an undisclosed target for treatment of Crohn’s disease and ulcerative colitis.
Intract Pharma is a biopharmaceutical company bringing disruptive oral biologics delivery solutions to significantly improve the efficacy and safety of emerging and established biotherapeutics and improve patient experience and outcome. The platform leverages the advantage of delivering large proteins/antibodies to the colon, while also protecting the biologics from enzymatic breakdown allowing tissue/systemic uptake to create next generation oral biologic medicines.
Dr Caroline Barelle, Chief Executive Officer at Elasmogen said:
“Securing this agreement with Intract enables us to deliver our incredibly potent anti-inflammatory soloMERs directly where they are needed in the GI tract, minimizing off-site adverse effects and maximizing clinical outcomes. We are really looking forward to working with the Intract team to expand our growing, differentiated pipeline of therapeutic biologics."
Elasmogen is a biopharmaceutical company located in the thriving biologics cluster in Aberdeen, Scotland. The Company is rapidly progressing a pipeline of next-generation soloMER™ products for the treatment solid-tumour cancers, systemic inflammatory diseases and inflammatory conditions of the gut. Discovering and developing soloMERs™ for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.
Vipul Yadav, Chief Executive Officer at Intract Pharma said:
‘’We are excited to build on our ongoing partnership with Elasmogen to create new transformative delivery options for innovative protein medicines to meet the unmet needs of millions of patients suffering from chronic inflammatory bowel disease. We believe oral targeted protein medicines are the future of IBD therapies and our collaboration with Elasmogen keeps building on our mission to bring innovative oral biologic therapies to patients.’’
The license agreement builds upon the research collaboration the two companies entered in to in May 2020 that involved pre-clinical evaluation of Soteria® and Phloral® technologies utilising Elasmogen’s multi-valent, novel inflammatory cytokine binding soloMER™ protein therapeutics. Acceleration of this research and development effort is facilitated by a recent £8 million funding round announced by Elasmogen and a £1.5 M Innovate Future Leaders grant. This grant funding in particular is specifically focused on Elasmogen's auto-immune programs.
Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).